UC Relief You Can Trust
Rely on DELZICOL®, the latest addition to our UC treatment
family—the family with 31 million prescriptions & counting.1
Save on your
Pay no more than $30/month
regardless of your commercial
*This offer is valid only for patients with commercial prescription drug insurance and applies only to DELZICOL® prescriptions. Depending on their insurance coverage, eligible insured patients pay no more than $30 for each of up to 12 prescription fills. Other eligible insured patients should check with their pharmacist for their co-pay discount. Maximum reimbursement limits apply; patient out-of-pocket expense may vary. See full Terms, Conditions, and Eligibility Criteria here or on back of card.
DELZICOL® delayed-release capsules may offer relief for those suffering from mildly to moderately active ulcerative colitis and help maintain remission of UC in adults.
If your doctor previously prescribed you Asacol®, you can feel confident transitioning to DELZICOL® because it offers the same safety and efficacy profile (bioequivalent) of Asacol®.
- IMS National Prescription Data: 1992-March 2014 (estimate derived from information used under license from IMS Health, Inc., which expressly reserves all rights, including rights of copying, distribution, and republication.)
Indication and Usage
DELZICOL® (mesalamine) delayed-release capsules are available only by prescription for the treatment of mildly to moderately active ulcerative colitis (UC) and for the maintenance of remission of UC in adults. You should take DELZICOL® at least 1 hour before a meal or 2 hours after a meal.
ASACOL® (mesalamine) delayed-release tablets are for the treatment of mildly to moderately active ulcerative colitis (UC) and the maintenance of remission of UC in adults.
DELZICOL® delayed-release capsules have been shown to be equivalent to ASACOL® delayed-release tablets.
Important Safety Information about DELZICOL® (mesalamine) delayed-release capsules
You should not take DELZICOL® if you are allergic to salicylates (including mesalamine, aspirin, or aspirin-containing products) or to any of the ingredients of DELZICOL®. Please tell your doctor if you think you are.
Reports of problems with kidney function have been associated with mesalamine-containing products like DELZICOL®. Tell your doctor if you have or have had problems with your kidneys. It is recommended that all patients have their kidney function checked before starting DELZICOL® and periodically while on therapy.
Products that contain mesalamine, like DELZICOL®, have been associated with a condition that may be difficult to distinguish from an ulcerative colitis flare-up. Symptoms include cramping, stomach ache, and bloody diarrhea, and sometimes fever, headache, and rash. If you experience any of these symptoms, talk to your doctor immediately. Your doctor may decide to discontinue your medication.
Tell your doctor if you are allergic to sulfasalazine, as you may also be allergic to DELZICOL® or drugs that contain or are converted to mesalamine. Some patients taking DELZICOL® or mesalamine-containing products have reported heart-related allergic reactions, such as inflammation of the heart muscle and inflammation of the lining of the heart. Tell your doctor if you have or have had a history of myocarditis or pericarditis as this may increase your likelihood of having these types of reactions.
Reports of liver failure have been associated with mesalamine-containing products like DELZICOL® in patients that have or have had liver disease. Tell your doctor if you have a problem with your liver.
Tell your doctor if you have a stomach blockage (pyloric stenosis), as this may delay the release of medication.
In clinical trials, common side effects reported included stomach pain, belching, pain, headache, back pain, diarrhea, rash, upset stomach, runny nose, flu symptoms, weakness or tiredness, flatulence, vomiting, fever, joint pain, constipation, and gastrointestinal bleeding.
Before starting DELZICOL®, tell your doctor about all medications you are taking. Mesalamine may increase the risk of kidney problems when used with non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen). Mesalamine may increase the risk of blood disorders when used with azathioprine and 6-mercaptopurine.
See Full Prescribing Information about DELZICOL®.
To report a side effects from one of our products, please call the Actavis Drug Safety Department at 1-800-272-5525.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or,
DELZICOL® is a registered trademark of Warner Chilcott Company, LLC.
Asacol® is a registered trademark of Medeva Pharma Suisse AG, used under license by Warner Chilcott Company, LLC.